Quick Answer
Biohaven Ltd. reported Cash and Equivalents of $229.96 million for fiscal year 2025.
Biohaven Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $229.96M | +132.0% |
| 2024 | $99.13M | -60.1% |
| 2023 | $248.40M | +21.2% |
| 2022 | $204.88M | +169.4% |
| 2021 | $76.06M | -7.8% |
| 2020 | $82.51M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $184.85M | +119.0% | +11.5% |
| June 30, 2025 | $165.80M | -30.7% | +68.5% |
| March 31, 2025 | $98.42M | -46.1% | -0.7% |
| December 31, 2024 | $99.13M | -60.1% | +17.5% |
| September 30, 2024 | $84.39M | -24.4% | -64.7% |
| June 30, 2024 | $239.15M | +62.0% | +30.9% |
| March 31, 2024 | $182.71M | +46.1% | -26.4% |
| December 31, 2023 | $248.40M | +21.2% | +122.4% |
- Biohaven Ltd. showed an increase of +132.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Biohaven Ltd.’s cash and equivalents has grown by 178.7% (from $82.51 million to $229.96 million).
- The most recent figure is from Biohaven Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: